A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
Study sponsor: Kiora Pharmaceuticals, Inc. · KPRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-09Actual
Enrollment · participants4Actual
Source updated2024-01-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.